Diagnostic Agents

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Diagnostic Agents Resource Center

Welcome to the MPR Diagnostic Agents Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

Diagnostic Agents

News

PET More Sensitive Than CT for Merkel Cell Carcinoma

Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for evaluation of the regional lymph node basin in patients with Merkel cell carcinoma (MCC).

CT Colonography Accurate for 10mm Adenomas

For patients at average-to-moderate risk of colon cancer, computed tomographic colonography (CTC) accurately detects adenomas 10mm or larger, but not smaller lesions.

Modified Fluorene Compound Potently Disrupts Amyloid-β

A modified version of fluorene counteracts amyloid beta (Aβ) peptide toxicity, and is more potent than the original fluorene compounds.

FISH + Cytology Beats Cytology Alone for Neoplasia Detection

For patients with diverse pathologies who undergo endoscopic ultrasonography with fine-needle aspiration, adding fluorescence in situ hybridization (FISH) detection methods to conventional cytology improves the sensitivity of cytology alone for detection of neoplastic lesions.

Early Noninvasive Paternity Test Based on SNPs Is Accurate

A new test, based on single-nucleotide polymorphisms, that only requires a maternal blood sample can correctly identify paternity as early as 8 weeks' gestation.

Toolbox

CLINICAL CHARTS

FDA VIDEO

Preventing Infections When Monitoring Blood Glucose

Using ESAs in patients with cancer-related anemia

0.75/ CE for Nurses

Based on data regarding the risks associated with erythropoietinstimulating agents (ESAs), the FDA recommended a Risk Evaluation Mitigation Strategy (REMS) program for these agents. Nurses play an important role in ensuring that prescribed treatment plans are appropriate for a particular patient (eg, laboratory parameters are appropriate).

Hepatitis C: Current Status and the Evolving Landscape

2.00/ CE for Pharmacists

This program enables pharmacists to stay current with the evolving landscape in the management of Hepatitis C. It includes a review of the disease, current treatment options, and agents in clinical development.